A new trading day began on Tuesday, with Contineum Therapeutics Inc (NASDAQ: CTNM) stock price up 7.00% from the previous day of trading, before settling in for the closing price of $4.43. CTNM’s price has ranged from $3.35 to $22.00 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Meanwhile, its annual earnings per share averaged -11.62%. With a float of $13.50 million, this company’s outstanding shares have now reached $19.14 million.
In an organization with 41 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 25.21%, operating margin of -24410.74%, and the pretax margin is -20591.32%.
Contineum Therapeutics Inc (CTNM) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Contineum Therapeutics Inc is 47.82%, while institutional ownership is 43.22%. The most recent insider transaction that took place on Nov 25 ’24, was worth 16,177. In this transaction Chief Scientific Officer of this company sold 1,010 shares at a rate of $16.02, taking the stock ownership to the 168,562 shares. Before that another transaction happened on Nov 18 ’24, when Company’s Chief Scientific Officer sold 6,190 for $16.38, making the entire transaction worth $101,421. This insider now owns 169,572 shares in total.
Contineum Therapeutics Inc (CTNM) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around -11.62% per share during the next fiscal year.
Contineum Therapeutics Inc (NASDAQ: CTNM) Trading Performance Indicators
Here are Contineum Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 21.47.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.93, a number that is poised to hit -0.45 in the next quarter and is forecasted to reach -3.01 in one year’s time.
Technical Analysis of Contineum Therapeutics Inc (CTNM)
Let’s dig in a bit further. During the last 5-days, its volume was 0.2 million. That was better than the volume of 80496.0 it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 69.37%. Additionally, its Average True Range was 0.46.
During the past 100 days, Contineum Therapeutics Inc’s (CTNM) raw stochastic average was set at 13.53%, which indicates a significant decrease from 98.58% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 152.72% in the past 14 days, which was higher than the 88.34% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.71, while its 200-day Moving Average is $11.72. However, in the short run, Contineum Therapeutics Inc’s stock first resistance to watch stands at $4.95. Second resistance stands at $5.15. The third major resistance level sits at $5.55. If the price goes on to break the first support level at $4.35, it is likely to go to the next support level at $3.95. The third support level lies at $3.75 if the price breaches the second support level.
Contineum Therapeutics Inc (NASDAQ: CTNM) Key Stats
With a market capitalization of 122.63 million, the company has a total of 25,872K Shares Outstanding. Currently, annual sales are 0 K while annual income is -42,260 K. The company’s previous quarter sales were 0 K while its latest quarter income was -15,990 K.
